Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?

TY - JOUR

T1 - Can early intervention with pharmacotherapy reduce the morbidity and mortality of chronic lymphocytic leukemia?

AU - Ma, Shuo

AU - Platanias, Leonidas C.

N1 - Funding Information: S Ma has received research funding from AbbVie, Acerta, Gilead Sciences, Pharmacyclics and Xeme Biopharma, honoraria for advisory board participation from AbbVie, Genentech, Gilead Sciences, Pharmacyclics and Janssen Pharmaceuticals. S Ma has also received speaker fees from Genentech and Pharmacyclics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

PY - 2018/7/24

Y1 - 2018/7/24

KW - CLL early intervention

KW - asymptomatic CLL

KW - early stage CLL

UR - http://www.scopus.com/inward/record.url?scp=85050344777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050344777&partnerID=8YFLogxK

U2 - 10.1080/14656566.2018.1498844

DO - 10.1080/14656566.2018.1498844

M3 - Editorial

C2 - 30020813

AN - SCOPUS:85050344777

SN - 1465-6566

VL - 19

SP - 1171

EP - 1175

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 11

ER -